Ishara Investments LP Invests $989,000 in Dianthus Therapeutics, Inc. $DNTH

Ishara Investments LP bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,000 shares of the company’s stock, valued at approximately $989,000. Ishara Investments LP owned approximately 0.06% of Dianthus Therapeutics as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $40,000. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth $64,000. Royal Bank of Canada grew its holdings in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $99,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. The trade was a 86.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 149,121 shares of company stock worth $12,635,454 in the last ninety days. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Trading Up 3.8%

Shares of DNTH opened at $81.89 on Thursday. Dianthus Therapeutics, Inc. has a 12-month low of $16.64 and a 12-month high of $96.50. The firm has a 50-day moving average price of $86.81 and a 200 day moving average price of $66.00. The firm has a market capitalization of $4.48 billion, a P/E ratio of -19.83 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNTH has been the subject of a number of research reports. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush upped their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.